FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3212530786> ?p ?o ?g. }

• W3212530786 endingPage "819" @default.
• W3212530786 startingPage "819" @default.
• W3212530786 abstract "Abstract Background Recommendations for 2 nd line treatment for relapsed multiple myeloma (MM) patients have been changing over the past two decades, given the introduction of novel agents, different side-effect profiles, and attempts at more individualized treatment approaches. We designed this study to characterize how 2 nd line treatment strategies have evolved over the last two decades for MM patients. Methods Patients with MM with at least one relapse treated with a 2 nd line regimen, seen at Mayo Clinic between 2003-2021, were included. To visualize trends in treatment choices we divided the study period into 2-year intervals and for descriptive purpose the period was divided into three 6-year intervals. We used 100% stacked area charts to show how the constituent parts of the whole have changed over time. The height of each colored stack represents the proportion of patients in that category at a given point in time. Results A total of 1439 patients were included. Patients were diagnosed between 2001 and 2018, the initiation of 2 nd line treatment occurred between June 2003 and February 2021. Median age at diagnosis was 62.7 years (interquartile range, 55.8-69.3), 60.0% were male. International Staging System stage I was present in 23.5% of patients, stage II in 32.9% and stage III in 28.8%. In the 1 st line therapy novel agents were used in 82.8% of cases, regimens based on proteasome inhibitors (PI) in 26.5%, immunomodulatory drugs (IMID) in 42.0% and combination of PI+IMID in 21.1%. Upfront autologous stem cell transplantation (ASCT) was performed in 50.1% of patients, and maintenance after 1 st line was used in 25.2%. For 2 nd line treatment, during 2003-2008 the majority were treated with doublets (70.5%), followed by triplets (14.8%) and salvage ASCT (7.7%) (Figure 1A). Patients were treated with IMID or PI-based therapy (50.7% and 21.8%, respectively); only 3.7% received PI+IMID and 20.1% of patients received alkylating agents/anthracyclines. The most frequently used regimens were lenalidomide-dexamethasone (RD, 32.2%) and bortezomib-dexamethasone (VD, 18.1%, Figure 1B). Between 2009-2014, the use of triplets in 2 nd line increased (43.0%), although doublets were still more common (50.9%). Like previous years, IMID-based therapy was most frequently used (37.3%), however, the use of PI-based therapy increased (36.0%). PI+IMID-based therapy was implemented in 17.9% of patient, and 27.3% received alkylating agents/anthracyclines. Most frequently used regimens included: RD (29.4%), bortezomib-cyclophosphamide-dexamethasone (CYBORD, 17.4%), bortezomib-lenalidomide-dexamethasone (VRD, 13.4%) and VD (13.3%). Finally, during 2015-2021, triplets were most common (68.9%), followed by doublets (23.0%). IMID- and PI+IMID-based therapies were most often implemented (34.2% and 31.1%, respectively), followed by PI-based therapy (26.8%). 28.1% of patients received monoclonal antibodies; only 15.9% received alkylating agents/anthracyclines. Most frequently used regimens include RD (13.8%), carfilzomib-RD (11.6%), daratumumab-RD (9.8%), CYBORD (9.3%), VRD (8.8%), daratumumab-pomalidomide-dexamethasone (5.9%) and daratumumab-VD (5.2%). Median time to next treatment (TTNT) from 2 nd line therapy has improved over the course of the three time periods (p&lt;0.01; Figure 1C): years 2003-2008, 10.4 months; years 2009-2014, 13.2 months; and years 2014-2021, 16.6 months. Similarly, the median overall survival from 1 st relapse has increased over the three intervals: 30.9 months, 48.4 months, and 65.8 months, respectively. Conclusions Over the past two decades, the effectiveness of 2 nd line treatment has improved, reflected by improved TTNT from 2 nd line therapy. With the introduction of new agents in 2012-2015 (carfilzomib, pomalidomide and daratumumab) and favorable results for triplets demonstrated in randomized trials, the triplet therapies started to be used more frequently. Over time, the landscape of 2 nd line therapies has become more diverse, which may reflect a more individualized approach to each patient. Moreover, the large variety of treatment strategies makes comparisons more and more challenging. Figure 1 Figure 1. Disclosures Kapoor: Ichnos Sciences: Research Funding; Karyopharm: Consultancy; BeiGene: Consultancy; Pharmacyclics: Consultancy; Sanofi: Consultancy; Amgen: Research Funding; Cellectar: Consultancy; Regeneron Pharmaceuticals: Research Funding; Glaxo SmithKline: Research Funding; Karyopharm: Research Funding; Sanofi: Research Funding; Takeda: Research Funding; AbbVie: Research Funding. Dispenzieri: Pfizer: Research Funding; Alnylam: Research Funding; Takeda: Research Funding; Oncopeptides: Consultancy; Sorrento Therapeutics: Consultancy; Janssen: Consultancy, Research Funding. Gertz: Akcea Therapeutics, Ambry Genetics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme: Honoraria; Aurora Biopharma: Other: Stock option; Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena: Consultancy; AbbVie Inc, Celgene Corporation: Other: Data Safetly & Monitoring; Ionis Pharmaceuticals: Other: Advisory Board. Dingli: Sanofi: Consultancy; Apellis: Consultancy; Novartis: Research Funding; Alexion: Consultancy; Janssen: Consultancy; GSK: Consultancy. Kumar: Adaptive: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bluebird Bio: Consultancy; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Tenebio: Research Funding; Carsgen: Research Funding; Beigene: Consultancy; Antengene: Consultancy, Honoraria; Roche-Genentech: Consultancy, Research Funding; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra-Zeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merck: Research Funding; Novartis: Research Funding; Sanofi: Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Oncopeptides: Consultancy." @default.
• W3212530786 created "2021-11-22" @default.
• W3212530786 creator A5001453763 @default.
• W3212530786 creator A5002248011 @default.
• W3212530786 creator A5012403700 @default.
• W3212530786 creator A5016853434 @default.
• W3212530786 creator A5023193953 @default.
• W3212530786 creator A5026574827 @default.
• W3212530786 creator A5033220547 @default.
• W3212530786 creator A5036263492 @default.
• W3212530786 creator A5054957898 @default.
• W3212530786 creator A5056260546 @default.
• W3212530786 creator A5058688409 @default.
• W3212530786 creator A5068637846 @default.
• W3212530786 creator A5071965755 @default.
• W3212530786 creator A5072502164 @default.
• W3212530786 creator A5074505099 @default.
• W3212530786 creator A5076611748 @default.
• W3212530786 creator A5077686486 @default.
• W3212530786 date "2021-11-05" @default.
• W3212530786 modified "2023-09-28" @default.
• W3212530786 title "Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience" @default.
• W3212530786 doi "https://doi.org/10.1182/blood-2021-151466" @default.
• W3212530786 hasPublicationYear "2021" @default.
• W3212530786 type Work @default.
• W3212530786 sameAs 3212530786 @default.
• W3212530786 citedByCount "0" @default.
• W3212530786 crossrefType "journal-article" @default.
• W3212530786 hasAuthorship W3212530786A5001453763 @default.
• W3212530786 hasAuthorship W3212530786A5002248011 @default.
• W3212530786 hasAuthorship W3212530786A5012403700 @default.
• W3212530786 hasAuthorship W3212530786A5016853434 @default.
• W3212530786 hasAuthorship W3212530786A5023193953 @default.
• W3212530786 hasAuthorship W3212530786A5026574827 @default.
• W3212530786 hasAuthorship W3212530786A5033220547 @default.
• W3212530786 hasAuthorship W3212530786A5036263492 @default.
• W3212530786 hasAuthorship W3212530786A5054957898 @default.
• W3212530786 hasAuthorship W3212530786A5056260546 @default.
• W3212530786 hasAuthorship W3212530786A5058688409 @default.
• W3212530786 hasAuthorship W3212530786A5068637846 @default.
• W3212530786 hasAuthorship W3212530786A5071965755 @default.
• W3212530786 hasAuthorship W3212530786A5072502164 @default.
• W3212530786 hasAuthorship W3212530786A5074505099 @default.
• W3212530786 hasAuthorship W3212530786A5076611748 @default.
• W3212530786 hasAuthorship W3212530786A5077686486 @default.
• W3212530786 hasBestOaLocation W32125307861 @default.
• W3212530786 hasConcept C119060515 @default.
• W3212530786 hasConcept C126322002 @default.
• W3212530786 hasConcept C146357865 @default.
• W3212530786 hasConcept C151730666 @default.
• W3212530786 hasConcept C2776135927 @default.
• W3212530786 hasConcept C2776364478 @default.
• W3212530786 hasConcept C2781413609 @default.
• W3212530786 hasConcept C512399662 @default.
• W3212530786 hasConcept C71924100 @default.
• W3212530786 hasConcept C86803240 @default.
• W3212530786 hasConceptScore W3212530786C119060515 @default.
• W3212530786 hasConceptScore W3212530786C126322002 @default.
• W3212530786 hasConceptScore W3212530786C146357865 @default.
• W3212530786 hasConceptScore W3212530786C151730666 @default.
• W3212530786 hasConceptScore W3212530786C2776135927 @default.
• W3212530786 hasConceptScore W3212530786C2776364478 @default.
• W3212530786 hasConceptScore W3212530786C2781413609 @default.
• W3212530786 hasConceptScore W3212530786C512399662 @default.
• W3212530786 hasConceptScore W3212530786C71924100 @default.
• W3212530786 hasConceptScore W3212530786C86803240 @default.
• W3212530786 hasIssue "Supplement 1" @default.
• W3212530786 hasLocation W32125307861 @default.
• W3212530786 hasOpenAccess W3212530786 @default.
• W3212530786 hasPrimaryLocation W32125307861 @default.
• W3212530786 hasRelatedWork W2053221007 @default.
• W3212530786 hasRelatedWork W2061253854 @default.
• W3212530786 hasRelatedWork W2089045987 @default.
• W3212530786 hasRelatedWork W2135221496 @default.
• W3212530786 hasRelatedWork W2355902447 @default.
• W3212530786 hasRelatedWork W2356105190 @default.
• W3212530786 hasRelatedWork W2435227317 @default.
• W3212530786 hasRelatedWork W2754890083 @default.
• W3212530786 hasRelatedWork W2971392718 @default.
• W3212530786 hasRelatedWork W3162511055 @default.
• W3212530786 hasVolume "138" @default.
• W3212530786 isParatext "false" @default.
• W3212530786 isRetracted "false" @default.
• W3212530786 magId "3212530786" @default.
• W3212530786 workType "article" @default.